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Abstract
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Considerable data support the phenomenological and temporal continuity between subclinical
psychosis and psychotic disorders. In recent years, neurocognitive deficits have increasingly been
recognized as a core feature of psychotic illness but there are few data seeking to elucidate the
relationship between subclinical psychosis and neurocogntive deficits in non-clinical samples. The
goal of the present study was to examine the relationship between subclinical positive and
negative symptoms, as measured by the Community Assessment of Psychic Experiences (CAPE)
and performance on the MATRICS Consensus Cognitive Battery (MCCB) in a large (n=303) and
demographically diverse non-clinical sample. We found that compared to participants with low
levels of subclinical positive symptoms, participants with high levels of subclinical positive
symptoms performed significantly better in the domains of working memory (p<.001), verbal
learning (p=.007) and visual learning (p=.014). Although comparison of participants with high and
low levels of subclinical negative symptoms revealed no differences in MCCB performance, we
found that individuals with high levels of subclinical negative symptoms performed significantly
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better on a measure of estimated IQ (WRAT-3 Reading subtest; p=.02) than those with low levels
of subclinical negative symptoms. These results are at odds with prior reports that have generally
shown a negative relationship between neurocognitive functioning and severity of subclinical
psychotic symptoms, and suggest some potential discontinuities between clinically significant
psychotic symptoms and sub-syndromal manifestations of psychosis.
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subclinical psychosis; cognition; MCCB

1. INTRODUCTION
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Considerable data support the phenomenological and temporal continuity between psychotic
disorders and subclinical manifestations of psychotic symptoms. Subclinical psychotic
symptoms are common in the general population with an estimated prevalence of 7.2% and
an annual incidence of 2.5% (Linscott & van Os 2013). The continuity between subclinical
psychosis and psychotic disorders is supported by longitudinal studies demonstrating that
high levels of subclinical psychotic symptoms predate the onset of psychotic illness
(Chapman et al 1994: Poulton et al 2000; Cannon et al 2002; Hanssen et al 2005; Wellham
et al 2009; Fisher et al 2013) as well as studies demonstrating substantial overlap in genetic
predisposition for clinical and subclinical levels of psychotic symptoms (Schulsinger 1976;
Kendler et al 1993; Tienari et al 2003). Moreover, a recent review and meta-analysis of the
literature on subclinical psychosis spanning over 2 decades (Linscott & van Os 2013) found
that nearly all of the demographic and experiential risk factors for psychotic disorders
predicted greater risk of subclinical psychosis.
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Over the last several decades, deficits across a range of cognitive skills have increasingly
been recognized as a core feature of psychotic illness (e.g. Barch & Ceaser 2012) but to
date, only a limited number of studies have examined whether similar deficits are associated
with subclinical psychosis in non-clinical samples. Data derived from studies of patients
with schizotypal personality disorder (SPD), however, have reported considerable overlap in
the neurocogntive deficits observed in SPD relative to schizophrenia (SZ) (Siever & Davis
2004 for a review). Because SPD is believed to represent an underlying predisposition for
SZ or “psychosis-proneness” (Claridge et al 1996), these data suggest that neurocogntive
deficits may be present across the lower ends of the psychosis continuum.
Studies examining the relationship between subclinical psychosis and neurocognitive
functioning in non-clinical samples have yielded inconsistent results and have been limited
in terms of the cognitive domains assessed (Giakoumaki 2012). For example, van Os and
colleagues (2005) found that in males, but not females, deficits in verbal fluency were
associated with severity of overall levels of subclinical psychosis. However, these authors
did not assess other domains of cognitive function. Contrary to the sex effect reported by
van Os and colleagues (2005), Simons et al. (2007) measured speed of processing and verbal
learning in an all female sample and found a significant association between both positive
and negative subclinical symptoms and decreased speed of processing. Laurent et al. (2001)
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examined only set-shifting with the Wisconsin Card Sorting Test (WCST) and concluded
that first-degree relatives of patients with SZ who had high scores of negative schizotypy on
the Chapman scales scored significantly worse than relatives who had low scores and worse
than healthy controls. Finally, Barnett and colleagues (2013) recently investigated whether
childhood cognitive function was associated with adult subclinical psychotic symptoms in a
large prospective birth cohort. They found that general cognitive ability (g) assessed at age
8, 11 and 15 was significantly predictive of subclinical psychotic symptoms in middle age.
Specifically, lower cognitive scores were associated with a greater likelihood of endorsing
subclinical psychotic symptoms. In this study, however, the association between current
cognitive function and endorsement of subclinical psychotic symptoms was not assessed.

NIH-PA Author Manuscript

Several limitations of the aforementioned studies should be noted. First, most of these
studies did not examine the effects of subclinical positive and negative symptoms separately.
Cross-sectionally, the relationship between symptom severity and cognitive impairment in
patients with SZ suggest that negative symptoms are more closely related to cognitive
deficits than positive symptoms (Harvey et al 2006). Thus, it is possible that the mixed
findings on the relationship between subclinical psychosis and cognitive function are
related, in part, to the focus on overall levels of subclinical psychosis. Additionally, the
cognitive domains examined have been limited and do not provide a comprehensive
assessment of the relation between subclinical psychosis and cognitive function across the
full range of domains typically observed to be impaired in SZ.
Thus, the goal of the present study was to examine this relationship in a large and
demographically diverse non-clinical sample comprehensively characterized for the
presence of subclinical psychotic symptoms and comprehensively assessed for
neurocogntive performance. Specifically, we aimed to evaluate whether the presence of high
levels of subclinical positive or negative symptoms as measured by the Community
Assessment of Psychic Experiences (CAPE) (Stefanis et al 2002) would be associated with
differential performance across the 7 neurocognitive domains assessed by the MATRICS
Consensus Cognitive Battery (MCCB) (Kern et al. 2008).

2. METHOD
NIH-PA Author Manuscript

2.1 Participants
The present sample comprised 303 healthy adult volunteers (53.13% female, 60.40%
Caucasian, Mage=38.12±14.29 years, MIQ (based on WRAT-3 Reading) = 103.14±8.43)
rrecruited from the general population via word of mouth, newspaper and internet
advertisements and posted flyers for an NIMH-funded study of subclinical psychosis in the
general population (MH086756 to PD). Participants were excluded if they had a past or
present affective or psychotic disorder diagnosis, active or recent substance abuse, or if they
had a history of CNS trauma, neurological disorder, or previously diagnosed learning
disability.
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2.2 Diagnostic Assessments
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Participants were initially administered the Structured Clinical Interview for the DSM-IV,
Non-Patient edition (SCID-I/NP) to rule out a past or present affective or psychotic disorder.
Information obtained from the SCID was compiled into a narrative case summary and
lifetime diagnosis was determined by two senior members of the ZHH faculty.
2.3 Assessment of Subclinical Psychosis
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Participants were administered the Community Assessment of Psychic Experiences (CAPE)
(Stefanis et al 2002), a 42-item, self-report questionnaire that measures three dimensions of
subclinical psychopathology including positive, negative and depressive symptoms. In the
present study, the positive and negative frequency dimensions were examined for relation to
neurocogntive functioning. Consistent with prior reports (van Os et al 2009), the positive
and negative subscale scores derived from the CAPE were not normally distributed. Indeed,
inspection of the data in our sample indicated that the CAPE subscale scores produced a
half-normal distribution. Thus, because standard statistical techniques could not be utilized,
we chose to dichotomize the subscale scores to facilitate the use of parametric tests. Initially,
scores were divided into quartiles for both the negative and positive dimensions of
subclinical psychotic symptoms. Any participant with a score at or above the 75th percentile
was assigned to the high symptom group while those falling below the 75th percentile were
assigned to the low symptom group. Thus, participants with a negative symptom subscale
score greater than 20, representing on average, a score 1.23 standard deviations above the
sample mean were considered to have high levels of negative symptoms. This score is
consistent with participants experiencing several infrequent negative psychotic-like
experiences or experiencing 2-3 recurrent experiences. Participants with a raw positive
symptom subscale score greater than 24, representing on average, a score 1.10 standard
deviations above the sample mean were considered to have high levels of positive
symptoms. This score is consistent with participants experiencing several infrequent positive
psychotic-like experiences or experiencing 1-2 recurrent experiences. It should also be noted
that the CAPE provides a measure of the distress associated with the experience of positive
and negative subclinical symptoms. In our data, these distress scores are highly correlated
with the frequency scores (rho > .9). Thus, these data were not examined as we believed
they were redundant with analyses based on the frequency scores.
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2.4 Neurocognitive Assessment: the MCCB
To assess neurocognitive functioning, The MATRICS Consensus Cognitive Battery
(MCCB) was administered to all participants. The MCCB is comprised of 10 standardized
cognitive measures that collectively capture functioning within seven cognitive domains that
are reliably impaired in schizophrenia (Nuechterlein et al 2004) including: Speed of
Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning,
Reasoning/Problem-solving, and Social Cognition. Participants in the current study
completed the MCCB in one visit. In the present study, T scores, corrected for age and sex,
derived from the MCCB scoring program were utilized as the primary dependent measures.
Additionally, we utilized the Wide Range Achievement Test-Third Edition-Reading Subtest
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(WRAT-3) as an estimate of IQ. The WRAT-3 Reading subtest is a test that assesses single
word reading skill and is highly correlated with full scale IQ (Kremen et al 2006).
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2.5 Statistical Analyses
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We initially sought to rule out differences between participants with high and low levels of
symptoms on age, sex, race and estimated IQ (based on WRAT-3 Reading subtest score).
Thus, we utilized t-tests or chi square tests, as appropriate, to examine the distributions of
these variables in those characterized as having high levels of positive symptoms vs. those
with low levels of positive symptoms and in those characterized as having high levels of
negative symptom vs. those with low levels of negative symptoms. Following these
analyses, we carried out two multivariate analysis of covariance (MANCOVA) comparing
the high and low positive symptom groups and the high and low negative symptoms groups
on all 7 MCCB domains. Because both race and general intelligence level have been shown
to influence performance on the tests comprising the MCCB (Nitzburg et al 2014; Rushton
and Jensen 2005; Diaz-Asper et al 2004), racial group (white and non-white) and WRAT-3
Reading subtest standard score were included as covariates in these analyses. We did not
include age and sex as covariates in these analyses because the MCCB T scores used as the
dependent measures were corrected for these demographic variables a priori using the
MCCB scoring program.

3. RESULTS
Comparison of the high and low positive symptom groups revealed no differences in age,
sex, race or estimated IQ (all p’s>0.19). These data are shown in Table 1. The MANCOVA
comparing the high and low positive symptom group revealed a significant overall effect
(F(7,260)=4.68; p<0.001) with post hoc tests indicating that participants with high levels of
positive symptoms scored significantly higher than participants with low levels of positive
symptoms on working memory (F(1,266)=16.47; p<0.001), verbal learning (F(1,266)=7.40;
p=0.007) and visual learning (F(1,266)=6.11; p=0.014). These data are show in Figure 1.
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It should be noted that some of our participants (N=42) were still within the age range of
risk for conversion to a psychotic disorder (i.e. < 30 years old), which could have
implications for cognitive functioning. Thus, to ensure that these results were not driven by
a subset of participants who could potentially transition to a psychotic disorder, we removed
participants under that age of 30 and re-ran the MANCOVA. The results of this analysis
were identical to the results obtained in the full sample. Additionally, because negative
symptoms are generally highly correlated with positive symptoms in both clinical and nonclinical samples (Linscott & van Os 2013), we followed up this analysis by examining 1) the
relation between positive and negative symptoms subscale scores and 2) the effect of
including the negative symptom subscale score as a covariate in the original MANCOVA
comparing the high and low positive symptom groups. In these analyses, the positive
symptom and negative symptom subscales were highly correlated (rho=.59; p<0.001).
Moreover, although the MANCOVA remained significant (F(7,259)=2.45; p=0.02), the post
hoc tests indicated that the difference between groups was no longer significant in the visual
learning domain. The differences in working memory and verbal learning however,
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remained significant (p=0.004 and p=0.03, respectively). Finally, to confirm that these
findings were not an artifact of the method we used to dichotomize our sample, we also
examined the correlations between the raw CAPE positive symptom subscale score and T
scores for the working memory and verbal learning domain. These analyses indicated the
CAPE positive symptom subscale was positively correlated with both working memory
(rho=0.14; p=0.02) and verbal learning (rho=0.12; p=0.04).
Comparison of the high and low negative symptom groups revealed no differences in age,
sex or race (all p’s>0.38). Comparison of the high and low negative symptom groups on our
measure of estimated IQ, however, indicated that participants with high levels of negative
symptoms had significantly better WRAT-3 Reading subtest standard scores than those
participants who had low levels of negative symptoms (t=2.38, p=0.02). These data are
shown in Table 1. The MANCOVA comparing the high and low negative symptom groups
across the 7 MCCB domains revealed no significant overall effect. These data are shown in
Figure 2.

NIH-PA Author Manuscript

In the present sample of 303 participants 47 participants were classified as high in both
positive and negative subclinical symptoms. Comparison of these participants to those
characterized as low in both symptom domains (N=150) using a MANCOVA identical to
the primary analyses, revealed that those with high levels of both subclinical positive and
negative symptoms performed significantly better in the domains of working memory
(p<0.001) and visual learning (p= .036) and trended toward better performance in the verbal
learning domain (p=0.053).
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Finally, to demonstrate that those in the high symptom groups were exhibiting symptoms
that could be considered clinically relevant, we assessed a sample of stable outpatients with
schizophrenia or schizoaffective disorder (N=184) recruited to an NIMH-funded study of
functional disability using the CAPE. We have previously demonstrated that scores obtained
on the CAPE in patient samples are valid and converge with those derived from clinicianadministered assessment scales (DeRosse et al 2014). Using this sample, which is well
matched in age and sex to the control sample in the present study, we compared the raw
CAPE scores in 1) our high positive symptom group to patients scoring within the lower half
of the distribution on the raw CAPE positive symptom score and 2) our high negative
symptom group to patients with scoring within the lower half of the distribution on the raw
CAPE negative symptom score. In the positive symptom analysis, the mean rank of the
controls was significantly higher than the mean rank of the patients (mean rank
controls=121.89 vs. mean rank patients=75.22; p<0.001). Similarly, in the negative
symptom analysis, the mean rank of the controls was significantly higher than the mean rank
of the patients (mean rank controls=119.58 vs. mean rank patients=50.00; p<0.001). These
data suggest that the symptom levels experienced by participants characterized as having
“high” subclinical symptoms are very similar to the mild symptoms observed in patients
with psychotic disorders.
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4. DISCUSSION
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The present findings suggest that high levels of positive subclinical symptoms in
participants with no history of an axis I psychotic or affective disorder is associated with
significantly better performance on measures of working memory, verbal learning, and
visual learning as measured by the MCCB. Moreover, although no effect of high negative
symptoms were noted on MCCB performance, ancillary findings indicated that those who
scored high on negative symptoms evidenced significantly better performance on a measure
of estimated IQ (WRAT-3 Reading subtest). These results are at odds with several prior
reports that have generally shown a negative relationship between neurocognitive
functioning and severity of subclinical psychotic symptoms (Laurent et al 2001; van Os et al
2005; Jabben et al 2007; Simons et al 2007).
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Our findings suggest some potential discontinuities between clinically significant psychotic
symptoms and sub-syndromal manifestations of psychosis. Specifically, if subclinical
psychosis represents a milder manifestation of the psychotic symptoms observed in
disorders such as SZ, we might expect to see cognitive impairment in the individuals
exhibiting high levels of subclinical psychotic symptoms similar to, albeit less severe than,
those observed in SZ. Indeed, it has generally been found that cognitive deficits consistently
accompany clinically significant psychotic symptoms (Bora, Yucel & Pentelis 2010;
Simonsen et al 2011; Lewandowski et al 2011). Contrary to this expectation, however, we
found better cognitive performance in individuals with high levels of subclinical psychosis.
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One possible explanation for this discrepancy is that symptom severity bears a correlational,
but not causative, relation to neurocognitive capacity. Support for this idea draws from a
series of complementary findings that suggest higher cognitive capacities act as a resilience
factor against clinically significant psychosis (Green 1996; Green, Kern & Heaton 2004;
Morrison et al 2004). First, patients with higher a priori cognitive capacities tend to have
better functional outcomes than patients with lower cognitive capacities (Green 1996;
Green, Kern & Heaton 2004). Moreover, the risk of transitioning from a prodromal state to a
psychotic disorder is significantly associated with impaired neurocognitive function (Keefe
et al 2006). Thus, when considering the population of individuals with high levels of
subclinical psychosis, those with low a priori cognitive capacities would be expected to
transition to clinically significant psychosis at a higher rate while those with higher
cognitive capacities would be expected to pool in comparatively larger numbers in the
subclinical domain because their high cognitive capacities protect them from transitioning.
If this is the mechanism at work, then the results of the present study could be attributed to
an inherent sampling bias. This conclusion would also suggest that the cognitive deficits
observed in psychotic disorders such as SZ may be independent from the positive and
negative symptoms characteristic of the illness. This is consistent with several lines of
research suggesting psychotic and cognitive symptoms may be separable and perhaps
independent characteristics of SZ (see Harvey et al 2006 for a review).
It is also possible, however, that there is a direct causative link between subclinical
psychosis and increased cognitive function. Several studies seeking to elucidate why
psychosis continues to persist despite the substantial decrements in reproductive fitness
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associated with it, have proposed that genetic variants associated with subclinical psychosis
may be beneficial in some way. Several studies have suggested that some of the risk variants
may be associated with heightened creativity or other intellectual abilities (Karlsson 1970;
Keefe & Magaro 1980; Green & Williams 1999; Burch et al 2006; Miller et al 2007; Batey
et al 2008; Claridge et al 2009; Keri 2009). For example, Karlsson (1970) found that patient
relatives, but not the patients themselves, had a significantly higher probability of being
persons of eminence than people in the general population, and Green and Williams (1999)
reported that individuals with higher scores on a test of schizotypy produced the most
creative responses on a divergent thinking battery.
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Several limitations of the present study should be noted. First, because the scores obtained
on the positive and negative symptom subscales of the CAPE were not normally distributed,
we opted to use an extreme groups analysis (Preacher et al. 2005), which has some inherent
limitations. This approach may have limited our ability to detect more nuanced relationships
between the level of subclinical psychotic symptoms and neurocognitive performance.
Moreover, because participants in the overall sample were only excluded if they met criteria
for a psychotic or mood disorder 16 participants met criteria for another axis I disorder (4
anxiety disorder NOS, 12 past substance abuse). However, to rule out the effects of these
diagnoses on our findings we re-ran both of the primary MANCOVA. The results of these
analyses were identical to what was found in the larger sample suggesting that the observed
differences were not driven by participants who met criteria for an axis I disorder. Despite
these limitations, however, the present findings contribute to a growing literature seeking to
elucidate the relationship between subclinical psychosis and neurocogntive functioning in
otherwise healthy adults. Additional studies in larger samples are warranted.
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Figure 1.

Comparison of participants classified as high vs. low on subclinical positive psychotic
symptoms across all 7 MCCB Domains. Mean T scores have been adjusted for race and
WRAT-3 performance. Significant differences are indicated by an asterisk (*).
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Figure 2.

Comparison of participants classified as high vs. low on subclinical negative psychotic
symptoms across all 7 MCCB Domains. Mean T scores have been adjusted for race and
WRAT-3 performance. No significant differences were found for any of the MCCB
domains.
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Participant demographics
Symptom Domain
% Minority

Age (SD)

% Female

WRAT-3 (SD)

37.91 (14.27)

48.54%

104.02(8.48)

38.53(14.40)

55.5%

102.68 (8.39)

38.91 (14.08)

53.26%

104.88 (7.41)**

37.77 (14.81)

53.08%

102.38 (8.74)

Positive Symptoms
High (N=103)
44.66%
Low (N=200)
37.00%
Negative Symptoms
High (N=92)
35.87%
Low (N=211)
41.23%
Note: Scores for the Wide Range Achievement Test-Third Edition-Reading Subtest (WRAT-3) are presented as standard scores.
**
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Participants classified as high on subclinical negative symptoms score significantly higher on the WRAT-3 than those classified as low on
negative symptoms (t (300)=2.38; p =.02).
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